GNF179Antiparasitic drug CAS# 1261114-01-5 |
- Lestaurtinib
Catalog No.:BCC2440
CAS No.:111358-88-4
- GW441756
Catalog No.:BCC5093
CAS No.:504433-23-2
- TLQP 21
Catalog No.:BCC2405
CAS No.:869988-94-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1261114-01-5 | SDF | Download SDF |
| PubChem ID | 58178960 | Appearance | Powder |
| Formula | C22H23ClFN5O | M.Wt | 427.9 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 125 mg/mL (292.12 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-amino-1-[3-(4-chloroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]ethanone | ||
| SMILES | CC1(C2=NC(=C(N2CCN1C(=O)CN)NC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)F)C | ||
| Standard InChIKey | KFSKTWYDIHJITF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H23ClFN5O/c1-22(2)21-27-19(14-3-7-16(24)8-4-14)20(26-17-9-5-15(23)6-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
GNF179 Dilution Calculator
GNF179 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.337 mL | 11.685 mL | 23.3699 mL | 46.7399 mL | 58.4249 mL |
| 5 mM | 0.4674 mL | 2.337 mL | 4.674 mL | 9.348 mL | 11.685 mL |
| 10 mM | 0.2337 mL | 1.1685 mL | 2.337 mL | 4.674 mL | 5.8425 mL |
| 50 mM | 0.0467 mL | 0.2337 mL | 0.4674 mL | 0.9348 mL | 1.1685 mL |
| 100 mM | 0.0234 mL | 0.1168 mL | 0.2337 mL | 0.4674 mL | 0.5842 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GNF179 is an optimized 8,8-dimethyl IP analog that exhibited the potency(4.8 nM against the multidrug resistant strain W2) in vitro metabolic stability and in vivo oral bioavailability.
- Siamenoside I
Catalog No.:BCN2540
CAS No.:126105-12-2
- 11-Oxo-mogroside V
Catalog No.:BCN2509
CAS No.:126105-11-1
- Rubiyunnanin C
Catalog No.:BCN8045
CAS No.:1261030-04-9
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- 6-O-Methylcerevisterol
Catalog No.:BCN6139
CAS No.:126060-09-1
- Atractyloside A
Catalog No.:BCN5383
CAS No.:126054-77-1
- GSK 525768A
Catalog No.:BCC1603
CAS No.:1260530-25-3
- 3-O-beta-Allopyranosyl-(1->4)-beta-oleandropyranosyl-11-O-isobutyryl-12-O-acetyltenacigenin B
Catalog No.:BCN6765
CAS No.:1260252-18-3
- Birinapant (TL32711)
Catalog No.:BCC2250
CAS No.:1260251-31-7
- TCS 21311
Catalog No.:BCC2443
CAS No.:1260181-14-3
- 3-Oxo-21alpha-methoxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
Catalog No.:BCN7028
CAS No.:1260173-73-6
- TAK-438
Catalog No.:BCC1182
CAS No.:1260141-27-2
- BAPTA-AM
Catalog No.:BCC5456
CAS No.:126150-97-8
- Icariside E5
Catalog No.:BCN6140
CAS No.:126176-79-2
- Spiranthol A
Catalog No.:BCN7893
CAS No.:126192-35-6
- LY2886721
Catalog No.:BCC3807
CAS No.:1262036-50-9
- Ginsenoside Rg4
Catalog No.:BCN2713
CAS No.:126223-28-7
- Agrimonolide 6-O-glucoside
Catalog No.:BCN6141
CAS No.:126223-29-8
- INCB3344
Catalog No.:BCC1648
CAS No.:1262238-11-8
- Uralsaponin C
Catalog No.:BCN7906
CAS No.:1262326-46-4
- 24-Hydroxy-licoricesaponin A3
Catalog No.:BCN7896
CAS No.:1262326-47-5
- Uralsaponin D
Catalog No.:BCN7895
CAS No.:1262489-44-0
- (2R,3S)-Dihydrodehydroconiferyl alcohol
Catalog No.:BCN7886
CAS No.:126253-41-6
- Fumitremorgin B
Catalog No.:BCN6453
CAS No.:12626-17-4
Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro.[Pubmed:29530849]
Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: AAC.02235-17.
Artemisinin (ART) resistance has spread through Southeast Asia, posing a serious threat to the control and elimination of malaria. ART resistance has been associated with mutations in the Plasmodium falciparum kelch-13 (Pfk13) propeller domain. Phenotypically, ART resistance is defined as delayed parasite clearance in patients due to the reduced susceptibility of early ring-stage parasites to the active metabolite of ART dihydroartemisinin (DHA). Early rings can enter a state of quiescence upon DHA exposure and resume growth in its absence. These quiescent rings are referred to as dormant rings or DHA-pretreated rings (here called dormant rings). The imidazolopiperazines (IPZ) are a novel class of antimalarial drugs that have demonstrated efficacy in early clinical trials. Here, we characterized the stage of action of the IPZ GNF179 and evaluated its activity against rings and dormant rings in wild-type and ART-resistant parasites. Unlike DHA, GNF179 does not induce dormancy. We show that GNF179 is more rapidly cidal against schizonts than against ring and trophozoite stages. However, with 12 h of exposure, the compound effectively kills rings and dormant rings of both susceptible and ART-resistant parasites within 72 h. We further demonstrate that in combination with ART, GNF179 effectively prevents recrudescence of dormant rings, including those bearing pfk13 propeller mutations.
Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes.[Pubmed:27933786]
ACS Infect Dis. 2016 Nov 11;2(11):816-826.
MMV007564 is a novel antimalarial benzimidazolyl piperidine chemotype identified in cellular screens. To identify the genetic determinant of MMV007564 resistance, parasites were cultured in the presence of the compound to generate resistant lines. Whole genome sequencing revealed distinct mutations in the gene named Plasmodium falciparum cyclic amine resistance locus (pfcarl), encoding a conserved protein of unknown function. Mutations in pfcarl are strongly associated with resistance to a structurally unrelated class of compounds, the imidazolopiperazines, including KAF156, currently in clinical trials. Our data demonstrate that pfcarl mutations confer resistance to two distinct compound classes, benzimidazolyl piperidines and imidazolopiperazines. However, MMV007564 and the imidazolopiperazines, KAF156 and GNF179, have different timings of action in the asexual blood stage and different potencies against the liver and sexual blood stages. These data suggest that pfcarl is a multidrug-resistance gene rather than a common target for benzimidazolyl piperidines and imidazolopiperazines.
UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes.[Pubmed:27642791]
Nat Microbiol. 2016 Sep 19;1:16166.
A molecular understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field. We used conventional drug resistance selection as well as a regime of limiting dilution at early stages of drug treatment to probe two antimalarial imidazolopiperazines, KAF156 and GNF179. The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection. Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed four parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in two previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt). Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants. Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy. As mutations in pfact and pfugt conveyed resistance against additional unrelated chemical scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.
